Novo Nordisk A/S ADR (NVO)
Novo Nordisk A/S ADR is a depositary receipt listed on the NYSE for Novo Nordisk A/S, a Denmark-based pharmaceutical company founded in 1923 and headquartered in Bagsvaerd. Through its subsidiaries, the company researches, develops, manufactures, and distributes medicines across two reportable segments: Obesity and Diabetes Care, and Rare Disease. Its portfolio includes treatments for diabetes, obesity, cardiovascular and other emerging therapy areas, as well as products for rare blood disorders, rare endocrine disorders, and hormone replacement therapy. Novo Nordisk also markets devices and digital tools such as NovoPen 6, NovoPen Echo Plus, Dose Check, growth hormone pens, and injection needles, and it offers Wegovy pill, an oral GLP-1 receptor agonist therapy for weight management. The company operates across Europe, North America, Asia Pacific, Latin America, the Middle East, and Africa, and it has collaborations with Anthropic and Orbis Medicines.
Jump directly to the stock analysis sections supported by the latest available data.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-NVO
|
$61.55
|
47.8% Upside
|
Undervalued
|
$45.50
|
9.3% Upside
|
Fair
|
Great
|
3.2%
|
February 3, 2027
|
10.9x
|
5.6x
|
3.7x
|
181 B
|
199.4 B
|
9.9%
|
71.6%
|
7.1
|
45.9%
|
63.3%
|